JP2018517660A5 - - Google Patents

Download PDF

Info

Publication number
JP2018517660A5
JP2018517660A5 JP2017549195A JP2017549195A JP2018517660A5 JP 2018517660 A5 JP2018517660 A5 JP 2018517660A5 JP 2017549195 A JP2017549195 A JP 2017549195A JP 2017549195 A JP2017549195 A JP 2017549195A JP 2018517660 A5 JP2018517660 A5 JP 2018517660A5
Authority
JP
Japan
Prior art keywords
inhibitor
lncrna
expression
pdgfr
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017549195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517660A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/056013 external-priority patent/WO2016150870A1/en
Publication of JP2018517660A publication Critical patent/JP2018517660A/ja
Publication of JP2018517660A5 publication Critical patent/JP2018517660A5/ja
Pending legal-status Critical Current

Links

JP2017549195A 2015-03-20 2016-03-18 周皮細胞長鎖非コーディングrna Pending JP2018517660A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102015003656.4 2015-03-20
DE102015003656 2015-03-20
PCT/EP2016/056013 WO2016150870A1 (en) 2015-03-20 2016-03-18 Pericyte long non-coding rnas

Publications (2)

Publication Number Publication Date
JP2018517660A JP2018517660A (ja) 2018-07-05
JP2018517660A5 true JP2018517660A5 (cg-RX-API-DMAC7.html) 2019-03-07

Family

ID=55586316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549195A Pending JP2018517660A (ja) 2015-03-20 2016-03-18 周皮細胞長鎖非コーディングrna

Country Status (5)

Country Link
US (1) US20180044672A1 (cg-RX-API-DMAC7.html)
EP (1) EP3271458A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018517660A (cg-RX-API-DMAC7.html)
CA (1) CA2980385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016150870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3641833B1 (en) * 2017-06-19 2025-07-23 Université de Lausanne Compositions for controlling cardiac fibrosis and remodeling
JP7577654B2 (ja) 2018-11-13 2024-11-05 リピゴン ファーマスーティカルス アー・ベー 脂肪酸代謝の調節に影響を与えるangptl4オリゴヌクレオチド
CN109517049B (zh) * 2018-11-16 2021-04-13 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) Linc00266-1多肽作为实体瘤标志物的应用
US10851376B2 (en) 2018-12-28 2020-12-01 The Florida International University Board Of Trustees Long noncoding RNAs in pulmonary airway inflammation
CN110699441A (zh) * 2019-06-18 2020-01-17 云南省玉溪市人民医院 一种检测骨质疏松症的生物标志物、该标志物的应用及检测方法
CN110403954B (zh) * 2019-07-19 2022-11-11 广东省实验动物监测所 LncRNA XLOC_110286的抑制剂在制备促进血管新生的药物中的应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN111118143B (zh) * 2020-01-16 2020-09-15 西安市红会医院 检测及靶向rp11-754b17.1的试剂及其在关节炎中的应用
CN111560427A (zh) * 2020-05-19 2020-08-21 苏州大学附属儿童医院 lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用
WO2024102894A2 (en) * 2022-11-11 2024-05-16 The Regents Of The University Of California Methods for treating monge's disease
CN117180297B (zh) * 2023-09-08 2024-09-20 广州医科大学附属第一医院(广州呼吸中心) 用于前列腺癌诊断、治疗以及预后评估的标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
EA019595B1 (ru) 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス, インコーポレイテッド PDGFRβおよびVEGF−Aを阻害するための組成物および方法
WO2013020097A1 (en) * 2011-08-03 2013-02-07 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide compounds for treating hearing and balance disorders

Similar Documents

Publication Publication Date Title
JP6496296B2 (ja) ヒトezh2の阻害剤、およびその使用方法
CA2962075C (en) USE OF FGFR MUTANT GENE PANELS IN IDENTIFYING CANCER PATIENTS WHO WILL BE SENSITIVE TO TREATMENT WITH AN FGFR INHIBITOR
JP6158833B2 (ja) ベータ−カテニン関連疾患を処置するための有機組成物
ES2863526T3 (es) Tratamiento de enfermedades relacionadas con la subunidad alfa del canal de sodio (SCNA), controlado por voltaje, mediante inhibición de la transcripción antisentido natural a SCNA
Tripathi et al. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
CN102781480B (zh) 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
JP2022508155A (ja) がんを治療する方法
CN102482671B (zh) 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
WO2013036403A1 (en) TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
CN102782134A (zh) 通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
US20220062379A1 (en) Methods and compositions for modulating immune dysregulation
WO2011025862A2 (en) Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
AU2019414608A1 (en) Oligomeric nucleic acid molecule and application thereof
US20220133767A1 (en) Targeting micrornas to overcome drug tolerance and resistance
JP2023098926A (ja) Tut4/7発現調節因子を含む癌予防又は治療用薬学的組成物
WO2017005773A1 (en) Use of catenin- beta 1-targeting micrornas for treating liver cancer
EP2760457A1 (en) Methods and pharmaceutical compositions for treating cancer
Cai et al. MicroRNA‑205 increases the sensitivity of docetaxel in breast cancer
EP3708680A1 (en) Compositions and methods for xi chromosome reactivation
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease
CN115461461A (zh) 用于促进免疫原性细胞死亡的miRNA-193a
CN111617247B (zh) 表皮生长因子受体激酶底物8类蛋白3在增强多靶点激酶抑制剂疗效中的用途
CN103305596B (zh) 人rnf138基因的用途及其相关药物
JP7231917B2 (ja) 癌細胞における免疫チェックポイント因子の発現抑制剤及び癌治療用医薬組成物
WO2022237974A1 (en) Krab-containing zinc finger protein and cancer